SPOTLIGHT: New data spurs plans for Alchemia therapy

Australia's Alchemia has announced plans to accelerate its work developing HyCAMP for colorectal cancer after reviewing preliminary Phase II data. The mid-stage study looked at the efficacy of HyCAMP compared with irinotecan. The experimental therapy is designed to improve drug targeting to increase efficacy and reduce toxicity. Researchers said that HyCAMP improved the median for "progression free survival" to 5.2 months from 2.4 months. Report | Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.